The Gem of the OTC: Ive never seen anything like this on the OTC
X 1. Cash Flow Positive Status - 4+ years X 2. Purchase building which houses their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products. X 3. Adderall IR $335 Million approved and launched X 4. Adderall XR $1.56 BILLION approved and launched X 5. In house marketing and distribution: Kirkov __6. Generic OxyContin- FIRST TO FILE Aug 17, 2023 $720 Million __7. Prevail over Purdue in Generic OxyContin infringement suit X 8. DEA increases manufacturing quotas of Adderall & Vyvance X 9. Double digit quarterly revenues in millions. __10. Full ownership of Adderall IR $ 335 Million __11. Full ownership of Adderall XR $ 1.56 BILLION __12. Generic Concerta- $1.2 BILLION submission X 13. Generic Vyvanse- $5.1 BILLION - submitted to FDA Dec 2023 __14. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge __15. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million __16. Patented Unique ADF (w/o naltrexone)-- NDA __17. Mikah ANDA (s) __18. Undisclosed (s) __19. Antimetabolite ANDA- Methotrexate -$600 Million __20. Undisclosed Antimetabolite ANDA- $42 Million X 21. Prasco/Burel Adderall agreement January 1st 2024 X 22. First shipment Adderal XR to PRASCO Dec 2023 __23. Generic Vyvanse Approval __24. Triple digit yearly revenues in millions. __25. European distribution Dexcel partnership approval by Israeli Health __26. Purchase or rent additional manufacturing and storage space for new ANDAs __27. DollarLand PPS __28. Uplist to the NASDAQ Exchange __29. THE Buy Out ! __30. Vegas Baby !!!!!!!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.